In the CLL context, Reiners et al. have shown that the soluble NKp30 ligand BAG6/BAT3 detected in the plasma of CLL patients suppresses NK cell cytotoxicity and even downregulates the expression of CD16 and CD56 on NK cells of healthy donors [148]. This evidence concerns the gene NCAM1 and B-cell chronic lymphocytic leukemia.